In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.
Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.
After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.
Marie Hindee experienced a breakthrough in her 15-year battle with chronic lymphocytic leukemia and small lymphocytic lymphoma after undergoing a cutting-edge therapy at Corewell Health Beaumont ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results